H

Harrow

Compounds ophthalmic formulations; markets branded drugs

National Senior Director - Field Reimbursement

Full-Time
No salary listed
Expert
Bachelor's, MBA
Remote in USA
RemoteRemote within the United States, with travel of up to 75%.
Biology & Biotech

About the job

Requirements
  • A bachelor's degree is required; an advanced degree such as an MBA or MHA is a plus.
  • At least 10 years of progressive experience in market access, reimbursement, or trade, including significant experience in buy-and-bill, specialty pharmaceutical, or biotech environments.
  • At least 5 years of people leadership experience, including building and managing field-based reimbursement or access teams.
  • Deep expertise in payer policy, medical and pharmacy benefit dynamics, coding including CPT, HCPCS, and ICD-10, billing workflows, and claims and appeals processes.
  • Proven ability to conduct and lead claims data analysis to drive business decisions and customer-facing recommendations.
  • A track record of setting strategy and driving measurable improvements in patient access and reimbursement outcomes.
  • Strong executive presence and experience presenting to and influencing senior internal and external stakeholders.
  • Working knowledge of compliance requirements governing reimbursement support programs, including the PhRMA Code, OIG guidance, and anti-kickback considerations.
Responsibilities
  • Build, lead, coach, and scale a national team of Field Reimbursement Managers while establishing a customer-first, results-oriented culture.
  • Define team structure, territory alignment, key performance indicators, and performance standards; conduct field visits, ride-alongs, and performance reviews.
  • Recruit and develop reimbursement talent and create career paths and training curricula for the Field Reimbursement Manager function.
  • Foster collaboration with Sales, Trade, Marketing, Market Access and Payer Strategy, Legal, and Compliance.
  • Set the national field reimbursement strategy for the Retina and Surgical buy-and-bill portfolio.
  • Provide physician practices and their staff with education on coverage policy, coding, billing, and claims submission for company brands.
  • Lead business reviews with key accounts to assess reimbursement performance, identify access barriers, and develop corrective action plans.
  • Serve as the senior escalation point for complex payer, coding, or claims issues in the field.
  • Maintain expertise in commercial, Medicare, Medicare Advantage, and Medicaid payer dynamics for buy-and-bill specialty products.
  • Provide guidance on HCPCS, CPT, and J-code assignment, ICD-10 coding, modifiers, prior authorization, and appeals for Retina and Surgical procedures.
  • Ensure team guidance is accurate, compliant, and appropriately limited to education rather than performing billing or coding for customers.
  • Direct claims analysis to identify reimbursement trends, payer denial patterns, coverage gaps, and access barriers at account, regional, and national levels.
  • Translate data insights into field action plans and customer-facing recommendations.
  • Partner with Market Access and Trade teams on payer strategy, contracting priorities, and policy engagement using field and claims intelligence.
  • Own reporting and dashboards tracking access metrics, team performance, and franchise-level reimbursement KPIs for executive leadership.
  • Ensure team activities comply with company policies, OIG guidance, and applicable state and federal regulations governing field reimbursement support and healthcare-provider interactions.
  • Partner with Legal and Compliance on training, materials review, and monitoring of field activities.
Desired Qualifications
  • Experience in Retina, Ophthalmology, or Surgical specialty markets.

About the company

Harrow focuses on eyecare pharmaceuticals, combining a compounding business (ImprimisRx) with a portfolio of FDA-approved branded drugs and biosimilars, plus biotech investments. Its products include customized compounded sterile and topical eye medications delivered directly to physicians and patients, alongside branded drugs acquired from other companies. The company differentiates itself by integrating a direct-to-physician compounding platform with an expanding branded drug portfolio, biosimilars, and owned production and distribution facilities across all 50 states. Its goal is to provide accessible, high-quality eye medications and grow its commercial and biotech assets to serve surgeons, hospitals, and patients nationwide.

Company Size

201-500

Company Stage

IPO

Headquarters

Nashville, Tennessee

Founded

1998

Get referred to Harrow

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue rose 11% to $70.7 million, with guidance reaffirmed at $350 million-$365 million.
  • A top-three PBM gave VEVYE access to millions of lives effective August 1, 2026.
  • BYOOVIZ launched July 2026, and TYRVAYA could add over $30 million revenue in 2027.

What critics are saying

  • VEVYE pricing and gross-to-net issues cut Q1 2026 revenue by $8 million.
  • OSRX appealed the October 2025 judgment, delaying Harrow's collection and distraction benefits.
  • TYRVAYA adds $20 million annual SG&A and $70 million contingent payments, pressuring margins.

What makes Harrow unique

  • Harrow bundles compounding, branded drugs, and biosimilars under one ophthalmology-only platform.
  • BYOOVIZ launched July 2026, entering the anti-VEGF market beside IHEEZO and TRIESENCE.
  • VEVYE, TYRVAYA, and VERKAZIA target dry-eye and allergic-eye niches with specialized distribution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

32%

1 year growth

31%

2 year growth

31%
Yahoo Finance
Aug 20th, 2026
Harrow reaffirms $350M-$365M guidance despite light H1, needs $235M-$250M in H2 to meet target

Harrow reported first-half 2026 revenue of around $115 million, below expectations due to VEVYE pricing changes. The company maintained full-year guidance of $350 million to $365 million, requiring $235 million to $250 million in second-half revenue. IHEEZO delivered record quarterly demand of 65,477 units despite losing pass-through reimbursement, whilst ordering accounts grew 32% year-over-year. VEVYE prescriptions increased 21% sequentially, outpacing the 14% broader market growth, with market share rising to 14.6%. TRIESENCE demand surged 162% year-over-year to 14,529 units. However, adjusted EBITDA remained negative at $1.2 million. The pending TYRVAYA acquisition adds $20 million in annual costs. Hedge fund ownership declined from 24 to 22 funds, whilst short interest stands at 20.14% of float.

Yahoo Finance
Aug 11th, 2026
Harrow reiterates $350M–$365M revenue guidance, plans $30M TYRVAYA acquisition

Harrow reported second-quarter revenue of $70.7 million, up 11% year-over-year, driven by stronger demand for VEVYE, IHEEZO and specialty products. The ophthalmic pharmaceutical company reiterated full-year revenue guidance of $350 million to $365 million and adjusted EBITDA guidance of $80 million to $100 million. VEVYE generated $29.4 million in quarterly revenue, up nearly 58% year-over-year, whilst IHEEZO contributed $15.6 million. Management expects second-half growth from improved VEVYE pricing, IHEEZO's 25% net price increase, and the BYOOVIZ and VERKAZIA launches. Harrow plans to acquire global rights to TYRVAYA for $30 million in cash, expecting more than $30 million of revenue in 2027 if the deal closes. The company also advanced pipeline programmes G-MELT and YOCHIL, targeting FDA submissions in 2027.

Associated Press
Jul 1st, 2026
Harrow launches BYOOVIZ biosimilar in $9B US anti-VEGF market under Samsung Bioepis deal

Harrow has announced the commercial launch of BYOOVIZ (ranibizumab-nuna) in the United States, an FDA-approved biosimilar referencing LUCENTIS. The launch follows Harrow's exclusive US commercialisation agreement with Samsung Bioepis, which also includes rights to OPUVIZ (aflibercept-yszy), another ophthalmology biosimilar. BYOOVIZ is approved for treating Neovascular Age-Related Macular Degeneration, Macular Edema following Retinal Vein Occlusion, and Myopic Choroidal Neovascularization. It was designated by the FDA as the first interchangeable ophthalmology biosimilar in the US. The product joins Harrow's expanding retina franchise, which includes IHEEZO and TRIESENCE. The company aims to strengthen its position in the estimated $9 billion US anti-VEGF market, providing retina specialists with buy-and-bill products for treating sight-threatening retinal diseases.

Yahoo Finance
Jun 10th, 2026
Harrow re-launches VERKAZIA to treat vernal keratoconjunctivitis in children

Harrow has re-launched VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, a prescription therapy for vernal keratoconjunctivitis (VKC), a serious allergic eye disease primarily affecting children. The re-launch includes a comprehensive commercial strategy focused on physician education, patient access and affordability initiatives. VERKAZIA is a calcineurin inhibitor immunomodulator that targets VKC's underlying inflammatory mechanisms and may reduce the need for steroid rescue, which carries risks including glaucoma or cataract formation. VKC can lead to sight-threatening conditions if left untreated. Chief Executive Officer Mark Baum said the re-launch aims to ensure dependable supply and remove access barriers for this evidence-based, steroid-sparing treatment. VERKAZIA represents the second of three priority products in Harrow's portfolio currently being executed.

Yahoo Finance
May 20th, 2026
B.Riley cuts Harrow price target to $60 amid pricing pressure but maintains buy rating

Harrow, Inc. (NASDAQ:HROW) had its price target reduced to $60 from $65 by B.Riley on 14 May, though the firm maintained its Buy rating. The adjustment followed first-quarter results impacted by weaker pricing for VEVYE and lowered near-term growth expectations. The Nashville-based ophthalmic pharmaceutical company reported first-quarter revenue of $44.2 million, including an $8 million non-recurring adjustment related to VEVYE commercial coverage. Despite pricing pressures, the company highlighted record VEVYE prescriptions and strong performance from IHEEZO and TRIESENCE, with unit demand rising 18% and doubling respectively year over year. Harrow reaffirmed full-year revenue guidance of $350–$365 million. B.Riley cited upcoming product launches, reimbursement coding catalysts and expanding commercial leverage as factors supporting stronger second-half performance.